BLB&B Advisors LLC Has $11.47 Million Stock Position in Danaher Co. (NYSE:DHR)

BLB&B Advisors LLC lessened its stake in Danaher Co. (NYSE:DHR) by 4.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,945 shares of the conglomerate’s stock after selling 2,192 shares during the quarter. BLB&B Advisors LLC’s holdings in Danaher were worth $11,465,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of DHR. Heck Capital Advisors LLC bought a new position in Danaher in the 4th quarter worth approximately $27,000. Decker Retirement Planning Inc. acquired a new stake in shares of Danaher in the 4th quarter valued at $31,000. Golden State Wealth Management LLC bought a new stake in shares of Danaher during the fourth quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher during the third quarter valued at $39,000. Finally, MidAtlantic Capital Management Inc. bought a new position in Danaher in the third quarter valued at about $40,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 1.5 %

Danaher stock opened at $206.92 on Friday. Danaher Co. has a twelve month low of $205.79 and a twelve month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The company has a 50 day moving average of $233.38 and a 200-day moving average of $252.10. The stock has a market capitalization of $149.45 billion, a PE ratio of 39.19, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the firm posted $2.09 earnings per share. On average, equities research analysts anticipate that Danaher Co. will post 7.77 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s payout ratio is 20.45%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 10.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Raymond James reissued a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Jefferies Financial Group cut their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. KeyCorp lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Scotiabank started coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. Finally, UBS Group decreased their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.